Compare ZDGE & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZDGE | RFL |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5M | 61.1M |
| IPO Year | 2016 | 2017 |
| Metric | ZDGE | RFL |
|---|---|---|
| Price | $2.84 | $1.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 71.5K | ★ 100.5K |
| Earning Date | 03-12-2026 | 03-16-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | ★ 73.85 | 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,398,000.00 | $917,000.00 |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $5.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $1.73 | $1.12 |
| 52 Week High | $4.70 | $3.19 |
| Indicator | ZDGE | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 43.03 |
| Support Level | $2.56 | $1.15 |
| Resistance Level | $3.43 | $1.32 |
| Average True Range (ATR) | 0.21 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 27.38 | 8.54 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.